Welcome to our dedicated page for Apellis Pharmace SEC filings (Ticker: APLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apellis Pharmaceuticals, Inc. filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company with common stock registered under the Exchange Act. The company’s 8-K reports cover product revenue disclosures for SYFOVRE and EMPAVELI, cash and financial-condition updates, and material agreements related to collaborations, royalty arrangements, financing consents, and strategic transaction activity.
Apellis filings also record governance and compensation matters, including board appointments, director compensation, executive separation and retention plans, and related equity-award provisions. These documents disclose formal corporate actions, capital-structure references, material-event reporting, and the company’s public-company obligations as a Delaware issuer.
Apellis Pharmaceuticals’ chief executive Cedric Francois reported major equity changes tied to the company’s merger with Biogen. Common shares tendered in the offer were exchanged for $41.00 per share in cash plus one contingent value right, which can pay up to an additional $4.00 in cash upon specified milestones. The filing shows large dispositions of common stock and stock options, both directly and through several family trusts, in connection with the tender offer and subsequent merger. Equity awards such as options and restricted stock units were cancelled and converted into rights to receive cash and CVRs, or, for higher‑strike options, were cancelled without consideration, reflecting standard change‑of‑control treatment for executive equity.
Apellis Pharmaceuticals’ Chief Medical Officer Caroline Baumal reported multiple equity changes tied to the closing of Biogen’s acquisition of Apellis. On May 14, 2026, her common shares were disposed of to the issuer and through the tender offer, and she received new stock awards as part of the transaction.
Under the merger terms, tendered Apellis common stock was exchanged for $41.00 in cash per share plus one contingent value right (CVR) of up to $4.00 per share, subject to specified milestones. Restricted stock units and in-the-money options were either converted into cash-and-CVR rights or cancelled, leaving Baumal with no remaining stock options reported after the transaction but new time-based stock awards.
Biogen Inc. filed an amended beneficial ownership report showing it now holds 0% of Apellis Pharmaceuticals’ common stock. The change follows Biogen’s acquisition of Apellis through a tender offer and merger.
Biogen’s subsidiary offered $41.00 in cash per share plus one non-transferable contingent value right per share, which can pay up to an additional $4.00 in cash if specified milestones are achieved. After the offer conditions were met, Biogen’s subsidiary accepted all validly tendered shares and was then merged into Apellis, leaving Apellis as a wholly owned Biogen subsidiary.
Apellis Pharmaceuticals, Inc. notifies removal of its Common Stock from Nasdaq Stock Market LLC via Form 25. Nasdaq certified compliance with 17 CFR 240.12d2-2 and the issuer complied with exchange rules governing voluntary withdrawal. The notice is signed on behalf of Nasdaq by Katelin Rowe, CDO Analyst.
Apellis Pharmaceuticals has completed its acquisition by Biogen through a tender offer and follow‑on merger, giving stockholders $41.00 in cash per share plus one contingent value right (CVR) worth up to an additional $4.00 in cash upon future milestones. The tender offer closed with 105,687,831 shares validly tendered, representing about 82.4% of outstanding shares, satisfying the minimum condition for closing.
After the merger, Apellis became a wholly owned Biogen subsidiary and its common stock will be delisted from Nasdaq, with SEC registration and reporting to be terminated. All Apellis equity awards were converted into cash and CVRs or into contingent rights tied to continued service. Holders of Apellis’ 3.500% Convertible Senior Notes due 2026 can either require cash repurchase at approximately $1,008.46 per $1,000 principal on June 30, 2026, or convert during the make‑whole period to receive $1,080.77 in cash plus 26.3411 CVRs per $1,000 principal. The aggregate cash paid for shares in the offer and merger is about $5.3 billion, excluding fees and any CVR payments.
Biogen's wholly owned purchaser accepted for payment 105,687,831 Shares tendered in the offer for Apellis, representing approximately 82.4% of Shares outstanding immediately prior to the offer's expiration. The offer provided $41.00 per Share in cash plus one contingent value right per Share for up to $4.00 in additional cash upon specified milestones. All conditions to closing were satisfied or waived and, pursuant to the Merger Agreement and Section 251(h) of the DGCL, Purchaser will merge with and into Apellis and the merger will be consummated on May 14, 2026. At the Effective Time, each outstanding Share (subject to limited exceptions) will be converted into the right to receive the Merger Consideration, the Shares will be delisted from Nasdaq, and Apellis will become a wholly owned subsidiary of Biogen.
Apellis Pharmaceuticals filed Amendment No. 3 to its Schedule 14D-9 supplementing its solicitation/recommendation statement regarding Biogen’s tender offer and proposed merger. The offer expired May 13, 2026, with 105,687,831 Shares validly tendered (~82.4% of outstanding). Purchaser accepted those Shares on May 14, 2026, and expects to consummate the merger on May 14, 2026 under Section 251(h) of the DGCL without a stockholder vote. At the effective time, remaining outstanding Shares (subject to narrow exceptions) will be converted into the merger consideration and Apellis will become a wholly owned subsidiary of Biogen, its Shares delisted from Nasdaq.
State Street Corporation reported passive ownership of Apellis Pharmaceuticals common stock. On 03/31/2026 State Street disclosed 6,845,031 shares beneficially owned, representing 5.4% of the class. The filing shows shared voting power of 6,603,712 and shared dispositive power of 6,845,031. The report lists multiple State Street-related entities that hold the position and was signed on 05/12/2026 by Elizabeth Schaefer, Senior Vice President and Chief Accounting Officer.
Biogen's subsidiary filed Amendment No. 2 to the Schedule TO to update the tender offer terms for all outstanding Apellis Pharmaceuticals common shares. The offer provides $41.00 per share in cash plus one contractual, non-transferable contingent value right (CVR) per share for up to $4.00 aggregate upon milestone achievement. This amendment states the Regulatory Condition was satisfied when the waiting period under the HSR Act expired at 11:59 p.m. Eastern Time on May 11, 2026, clearing a required antitrust review step. Signatures are dated May 12, 2026.
Apellis Pharmaceuticals amends its Schedule 14D-9 to state that the Hart-Scott-Rodino waiting period applicable to the tender offer and merger expired at 11:59 p.m. Eastern Time on May 11, 2026, and that the HSR-related condition to the offer has been satisfied.
The offer by a Biogen subsidiary proposes $41.00 per share in cash plus one non-transferable contingent value right per share to receive up to $4.00 in additional cash upon achievement of specified milestones.